Behavioural interaction between the NMDA antagonist MK-801 and the dopaminergic antagonist haloperidol: Support for a balance model

Journal of Psychopharmacology

Volumn 9, Issue 1, 1995, Pages 9-15

  Dai, Huiliang ^a   Carey, Robert J ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

behaviour; dopamine; dose response; haloperidol; MK 801

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; CORTICOSTERONE; DIZOCILPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; HALOPERIDOL; HOMOVANILLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DOPAMINE BLOOD LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG COMPETITION; DRUG EFFECT; HABITUATION; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RAT; SEROTONIN BLOOD LEVEL;

EID: 0028900427     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/026988119500900102     Document Type: Article

References (38)

1. Behrens S., Gattaz W.F. (1992) MK-801 induced stereotypies in rats are decreased by haloperidol and increased by diazepam. J Neural Transm Gen Sect 90: 219-224
2. Carlsson M., Carlsson A. (1989a) Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 77: 65-71
3. Carlsson M., Carlsson A. (1989b) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221-226
4. Carlsson M., Carlsson A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272-276
5. Crossman A.R., Peffs D., Boyce S., Luquin M.R., Sambrook M.A. (1989) Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology 28: 1271-1273
6. Dai H., Carey R.J. (1994a) Time course effects of MK-801: the relationship between brain neurochemistry and behavior. Brain Res Bull (in press)
7. Dai H., Carey R.J. (1994b) The NMDA antagonist MK-801 can impair attention to exteroceptive stimuli. Behav Brain Res 62: 149-156
8. Derlet R.W., Albertson T.E., Rice P. ( 1990) Antagonism of cocaine, amphetamine, and methamphetamine toxicity. Pharmacol Biochem Behav 36: 745-749
9. Gandolfi O., Rimondini R., Dall'Olio R. (1992) The modulation of dopaminergic transmission in the striatum by MK-801 is independent of presynaptic mechanisms. Neuropharmacology 31: 1111-1114
10. Hauber W., Schmidt W.J. (1990) The NMDA antagonist dizocilpine (MK-801) reverses haloperidol-induced movement initiation deficits. Behav Brain Res 41: 161-166
11. Hiramatsu M., Cho A.K., Nabeshima T. (1989) Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166: 359-366
12. Hoffman D.C., Donovan H., Cassella J.V. (1993) The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology (Berl) 111: 339-344
13. Holemans S., Javoy F., Agid Y., Laterre E.C., Maloteaux J.M. (1991) [3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy. Brain Res 565: 154-157
14. Hoshino Y., Kaneko M., Kumashiro H., Tachibana R. (1985) Endocrinological function in schizophrenic patients under haloperidol treatment: plasma PRL, HGH and 5HT levels after L-5HTP loading. Folia Psychiatr Neurol Jap 39: 25-31
15. Imperato A., Scrocco M.G., Bacchi S., Angelucci L. (1990) NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187: 555-556
16. Kalivas P.W., Duffy P., Barrow J. (1989) Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J Pharmacol Exp Ther 251: 378-387
17. Kashihara K., Hamamura T., Okumura K., Otsuki S. (1990) Effect of MK-801 on endogenous dopamine release in vivo. Brain Res 528: 80-82
18. Kim J.S., Kornhuber H.H., Brand U., Menge H.G. (1981) Effects of chronic amphetamine treatment on the glutamate concentration in cerebrospinal fluid and brain: implications for a theory of schizophrenia. Neurosci Lett 24: 93-96
19. Klockgether T., Turski L. (1990) NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 28: 539-546
20. Krebs M.O., Kemel M.L., Gauchy C., Desban M., Glowinski J. (1989) Glycine potentiates the NMDA-induced release of dopamine through a strychnine-insensitive site in the rat striatum. Eur J Pharmacol 166: 567-570
21. Kulkarni S.K., Verma A. (1991) Glutamate-dopamine receptor interaction in neuropsychiatric disorders. Drugs Today 27: 255-261
22. Kuribara H., Asami T., Ida I., Tadokoro S. (1992) Characteristics of the ambulation-increasing effect of the noncompetitive NMDA antagonist MK-801 in mice: assessment by the coadministration with central-acting drugs. Jap J Pharmacol 58: 11-18
23. Lehmann Masten V.D., Geyer M.A. (1991) Spatial and temporal patterning distinguishes the locomotor activating effects of dizocilpine and phencyclidine in rats. Neuropharmacology 30: 629-636
24. Leviel V., Gobert A., Guibert B. (1990) The glutamate-mediated release of dopamine in the rat striatum: further characterization of the dual excitatory-inhibitory function. Neuroscience 39: 305-312
25. Liljequist S., Ossowska K., Grabowska-Anden M., Anden N.E. (1991) Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur J Pharmacol 195: 55-61
26. Lodge D., Johnson K.M. (1990) Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 11: 81-86
27. Loscher W., Honack D. (1993) Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats. Eur J Pharmacol 238: 191-200
28. Loscher W., Annies R., Honack D. (1991) The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett 128: 191-194
29. Martin G.E. (1986) Catecholamine release within the striatum of the freely moving rat. Ann NY Acad Sci 473: 151-159
30. Morelli M., Di Chiara G. (1990) MK-801 potentiates dopaminergic D 1 but reduces D 2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur J Pharmacol 182: 611-612
31. Schmidt W.J., Bubser M. (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32: 621-623
32. Steinberg G.K., Kunis D., DeLaPaz R., Poljak A. (1993) Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile. Neurol Res 15: 174-180
33. Tiedtke P.I., Bischoff C., Schmidt W.J. (1990) MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm Gen Sect 81: 173-182
34. Ujike H., Tsuchida H., Kanzaki A., Akiyama K., Otsuki S. (1992) Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitization. Life Sci 50: 1673-1681
35. Wachtel H., Turski L. (1990) Glutamate: a new target in schizophrenia? Trends Pharmacol Sci 11: 219-220
36. Werling L.L., Jacocks H.M., McMahon P.N. (1990) Regulation of [3H] dopamine release from guinea pig striatum by NMDA receptor/channel activators and inhibitors. J Pharmacol Exp Ther 255: 40-45
37. Whitton P.S., Biggs C.S., Pearce B.R., Fowler L.J. (1992) Regional effects of MK-801 on dopamine and its metabolites studied by in vivo microdialysis. Neurosci Lett 142: 5-8
38. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F., Corsini G.U. (1992) MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J Neurochem 59: 733-739